102. Choosing a Long-Term Treatment Option NMOSD

Selecting treatment options for NMOSDПодробнее

2021 RNDS | Neuromyelitis Optica Spectrum Disorder (NMOSD)Подробнее

CMSC 2020 Day 1: Brian Weinshenker, MD on NMOSD: Emerging Treatment OptionsПодробнее

2022 Pre-RNDS | Neuromyelitis Optica Spectrum Disorder (NMOSD)Подробнее

Dr. Anu Jacob l NMOSD Therapy UpdateПодробнее

206. History, Diagnosis, and Management of NMOSDПодробнее

2021 RNDS | A Treatment Option for NMOSDПодробнее

2022 RNDS | What are the long-term treatments for NMOSD and MOGAD?Подробнее

101. I have NMOSD. Now What?Подробнее

Consistent efficacy of inebilizumab across newly presenting and previously treated NMOSD casesПодробнее

Kathleen Hawker, MD: Clinical Findings for Satralizumab in Treating NMOSDПодробнее

303. Long-Term Therapies in NMOSDПодробнее

Recent progress and future needs in NMOSD treatmentПодробнее

2020 RNDS | Long-term Treatments for Preventing RelapsesПодробнее

SAkura: long-term safety and efficacy of satralizumab for NMOSDПодробнее

102. Meteoroid and cosMOG Clinical Trials for MOGAD TreatmentsПодробнее

2020 RNDS | What is Neuromyelitis Optica Spectrum Disorder (NMOSD)?Подробнее

106. Symptom Management Mini-Series | Managing Pain in NMOSDПодробнее